31.07.2013 • News

BASF Aims to Top 2013 Figures Despite Weaker H1

The world's largest chemical producer found the going tougher than expected in the first half of 2013. Sales revenue increased by 4% to €8.1 billion, and EBIT before special items by 2.5% to €4 billion, In Q2, sales added 3% year-on-year to just under €18.4 billion, thanks to higher volumes and a strong performance of the Agriculture and Oil & Gas segments. However, EBIT before special items declined 5% to €1.8 billion. Meeting the earnings forecast announced at the beginning of 2013 now appears "significantly more challenging," BASF CEO Kurt Bock said, but stressed that the group still aims to top the 2012 figures. 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read